Table of Contents

Abra, R. M., Hunt, C. A., Fu, K. K., Peters, J. H.: Delivery of therapeutic doses of doxorubicin to the mouse lung using lung-accumulating liposomes proves unsuccessful 98
Adenis, L., see Hecquet, B., et al. 177
Aisner, J., see Gerad, H., et al. 162
Akaza, H., see Niijima, T., et al. S 79
Anderson, L., see Edsmyr, F., et al. S 67
Angelelli, B., see Camaggi, C. M., et al. 19
Ann, H. J., see Kim, S. K., et al. S 22
Arcolano, L., see Kimball, P. M., et al. 137
Armstrong, R. D., Connolly, K. M., Kaplan, A. M., Cadman, E.: Mechanism of cytotoxic of 5'-deoxy-5-fluorouridine 102
Asechi, S., see Ohi, Y., et al. S 83
Atassi, G., see Vandendris, M., et al. 182

Bachur, N. R., see Banks, A. R., et al. 91
Badaracco, G., see Greco, C., et al. 38
Baer, J., see Sharma, H., et al. 5
Balcerzak, S. P., see Bukowski, R. M., et al. 48
Balkwill, F. R., see Rohatiner, A. Z. S., et al. 56
Banks, A. R., Jones, T., Koch, T. H., Friedman, R. D., Bachur, N. R.: Prevention of adriamycin toxicity 91
Barnard, D. L., see Child, J. A., et al. 153
Beardsley, P., see Fram, R., et al. 43
Benjamin, R. S., see Seifert, W. E., Jr., et al. 120
Bhasin, R. R., Nogeirie, C. P.: Combination chemotherapy (High-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer 106
Bianchi, M., see Garattini, E., et al. 51
Bock, M., see Jackson, H., et al. 200
Bouffioux, C., see Schulman, C. C., et al. S 32
Bukowski, R. M., McCracken, J. D., Balcerzak, S. P., Fabian, G. J.: Phase II Study of Chlorozotocin in Islet Cell Carcinoma: A Southwest Oncology Group Study 48
Burchenal, J. H., see Warrell, R. P., et al. 134

Cadman, E., see Armstrong, R. D., et al. 139
Calman, K., see Welsh, J., et al. 66
Camaggi, C. M., Strocchi, E., Giovannini, M., Angelelli, B., Costanti, B., Zebini, E., Ferrari, P., Pannuti, F.: Medroxyprogesterone Acetate (MAP) Plasma Levels After Multiple High-Dose Administration in Advanced Cancer Patients 19
Cangh, P. J. Van, see Schulman, C. C., et al. S 32
Caprioli, R. M., see Seifert, W. E., Jr., et al. 120
Cartwright, S. C., see Child, J. A., et al. 153
Case, L. D., see Jackson, D. V., Jr., et al. 191
Cash, H., see Welsh, J., et al. 66
Case, D., see Shipp, S. K., et al. 130
Catalani, P., see Garattini, E., et al. 51
Chantrie, M., see Schulman, C. C., et al. S 32
Charlton, D., see Welsh, J., et al. 66
Chiang, C.-P., see Huang, C.-H. S 91
Child, J. A., Barnard, D. L., Cartwright, S. C., Lauder, I., Simmons, A. V., Stone, J., Thorogood, J.: A pilot study of clinical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL) 153
Child, J. A., see Smith, P. H., et al. S 25
Chin, H., see Nakagami, Y., et al. S 47
Cho, J. H., see Kim, S. K., et al. S 22
Christian, R. M., see Shipp, S. K., et al. 130
Christian, R. M., see Jackson, D. V., Jr., et al. 191
Clarkson, B. D., see Straus, D. J., et al. 80
Cohen, M. B., see Nguyen, B. T., et al. 117
Colls, B. M., Robson, R. A., Robinson, B. A., Tisch, G. W.: Serum profiles and safety of intermediate-dose (500–1,000 mg) methotrexate following IV and IM administration 188
Colombo, N., see Sessa, C., et al. 33
Colombo, T., see Garattini, E., et al. 51
Connolly, K. M., see Armstrong, R. D., et al. 102
Coonley, C. J., see Warrell, R. P., et al. 134
Cooper, M. R., see Shipp, S. K., et al. 130
Cooper, M. R., see Jackson, D. V., Jr., et al. 191
Costanti, B., see Camaggi, C. M., et al. 19
Cowens, J. W., see Pendyala, L., et al. 23
Creaven, P. J., see Pendyala, L., et al. 23
Crowther, D., see Sharma, H., et al. 5

Dalesio, O., see Smith, P. H., et al. S 25
Deeb, G., see Gaver, R. C., et al. 139
Demaille, A., see Hecquet, B., et al. 177
Denis, L. J., see Schulman, C. C., et al. S 32
D'Incalci, M., see Sessa, C., et al. 33
D'Incalci, M., see Garattini, E., et al. 51
Dombernowsky, P., Lund, B., Hansen, H. H.: Phase-I Study of α-1,3,5-Triglycidyl-s-triazinetrione (NSC 296934) 59
Donaldson, E. S., see Pavlik, E. J., et al. 8
Donelli, M. G., see Garattini, E., et al. 51
Dufour, M., see Lazarus, P., et al. 159
Dumont, P., see Vandendris, M., et al. 182

Echo, D. A., Van, see Gerad, H., et al. 162
Edsmyr, F., Anderson, L., Esposti, P.-L.: Intravesical chemotherapy in urinary bladder cancer S 67
Egan, E., see Fram, R., et al. 43
Egorin, M. J., see Gerad, H., et al. 162
Ellis, N., see Kimball, P. M., et al. 137
Endler, A. T., see Porpaczy, P., et al. 172
Erps, P. Van, see Schulman, C. C., et al. S 32
Esposti, P.-L., see Edsmyr, F., et al. S 67

Fabian, G. J., see Bukowski, R. M., et al. 48
Fai, C. Y., see Ohi, Y., et al. S 83
Falkson, G., Falkson, H. C.: A Phase II Study of High-Dose Medroxyprogesterone Acetate in Advanced Breast Cancer 16
Falkson, G., Pretorius, H. L., Falkson, H. C., Schoeman, H. S.: Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer 203
Falkson, H. C., see Falkson, G. 16
Falkson, H. C., see Falkson, G., et al. 203
Falkson, G., Vorobiof, D. A., Lerner, H. J.: A phase II study of m-AMSA in patients with malignant mesothelioma 94
Ferrari, P., see Camaggi, C. M., et al. 19
Flanigan, R. C., see Pavlik, E. J., et al. 8
Fox, B. W., see Sharma, H., et al. 5
Fox, B. W., see McGown, A. T., et al. 113
Fram, R., Major, P., Egan, E., Beardsley, P., Rosenthal, D., Kufe, D.: A Phase I–II Study of Combination Therapy with Thymidine and Cytosine Arabinoside 43
Friedell, G. H.: Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project S 13
Friedman, R. D., see Banks, A. R., et al. 91
Fu, K. K., see Abra, R. M., et al. 98
Fujioka, H., see Kotake, T., et al. S 38
Fujita, J., see Uyama, T., et al. S 59
Fukushima, S., see Ohtani, M., et al. S 64

Gál, F., see Kralovánszky, J., et al. 167
Galligioni, E., see Veronesi, A., et al. 35
Garattini, E., Colombo, T., Donelli, M. G., Catalani, P., Bianchi, M., D'Incalci, M., Pantarotto, C.: Distribution, Metabolism, and Irreversible Binding of Hexamethylmelamine in Mice Bearing Ovarian Carcinoma 51
Gaver, R. C., Deeb, G., Pittman, K. A., Issell, B. F., Mittelman, A., Smyth, R. D.: Disposition of orally administered ^{14}C-prednimustine in cancer patients 139
Georgopoulos, A., see Porpaczy, P., et al. 172
Gerad, H., Egorin, M. J., Whitacre, M., Echo, D. A., Van, Aisner, J.: Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia 162
Germina, J. St., see Lazarus, P., et al. 159
Giovannini, M., see Camaggi, C. M., et al. 19
Glashan, R. W.: Treatment of carcinoma in situ of the bladder with doxorubicin (Adriamycin) S 35
Glatte, P., see Osieka, R., et al. 147
Gowing, N. F., see Stuart-Harris, R. C., et al. 69
Greco, C., Zupi, G., Badaracco, G.: Influence of Scheduling on Therapeutic and Toxic Effect of AMSA in Lewis Lung Carcinoma 38
Greco, W., see Pendyala, L., et al. 23
Griffen, W. O., see Pavlik, E. J., et al. 8
Grigolleto, E., see Veronesi, A., et al. 35

Hanafusa, A., see Ohi, Y., et al. S 83
Hansen, H. H., see Dombernowsky, P., et al. 59
Hanson, M. B., see Pavlik, E. J., et al. 8
Harker, W. G., see Torti, F. M. S 1
Harper, P. G., see Stuart-Harris, R. C., et al. 69
Harrison, S. D., Jr.: An Investigation of the mouse as a model for vincristine toxicity 62
Hecquet, B., Adenis, L., Demaille, A.: In vitro interactions of TNO_6 with human plasma 177
Heimann, R., see Vandendris, M., et al. 182
Hickie, R. A., see Wu Wei, J., et al. 86
Hiraoka, Y., see Nakagami, Y., et al. S 47
Hixon, S., see Kimball, P. M., et al. 137
Hofstädter, F., see Jakse, G. S 74
Honma, Y., Kasukabe, T., Okabe-Kado, J., Hozumi, M., Tsushima, S., Nomura, H.: Antileukemic effect of alkyl phospholipids. I. Inhibition of proliferation and induction of differentiation of cultured myeloid leukemia cells by alkyl ethyleneglycophospholipids 73
Honma, Y., Kasukabe, T., Okabe-Kado, J., Hozumi, M., Tsushima, S., Nomura, H.: Antileukemic effect of alkyl phospholipids. II. Prolongation of survival times of leukemic mice by alkyl ethyleneglycophospholipids 77
Hozumi, M., see Honma, Y., et al. 73
Hozumi, M., see Honma, Y., et al. 77
Huang, C.-H., Chiang, C.-P.: Bladder instillation of Adriamycin in the treatment of bladder cancer S 91
Hunt, C. A., see Abra, R. M., et al. 98

Ingargiola, G. B., see Pavone-Macaluso, M., et al. S 16
Ishikawa, S., see Kanoh, S., et al S 51
Issell, F. B., see Gaver, R. C., et al. 139
Ito, N., see Ohtani, M., et al. S 64
Iwaguchi, T., see Shimuzu, M., et al. 144

Jackson, D. V., see Shipp, S. K., et al. 130
Jackson, D. V., Jr., Muss, H. B., Richards, F., II, White, D. R., Spurr, C. L., Cooper, M. R., Christian, R. M., Trahey, T. F., Case, L. D., Wells, H. B.: CCNU in combination chemotherapy for advanced histologically unfavorable non-Hodgkin's lymphoma 191
Jackson, H., Bock, M., Jackson, N. C., Lendon, M.: The testis. A protected environment for leukaemic cells against cyclophosphamide in a mouse model 200
Jackson, N. C., see Jackson, H., et al. 200
Jakse, G., Hofstädter, F.: Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells S 74
Japanese Urological Cancer Research Group for Adriamycin, see Niijima, T., et al. S 79
Jiang, T. L., Liu, R. H., Salmon, S. E.: Antitumor Activity of Didemnin B in the Human Tumor Stem Cell Assay 1
Jones, T., see Banks, A. R., et al. 91

Kakinoki, T., see Ohi, Y., et al. S 83
Kanoh, S., Umeyama, T., Nemoto, S., Ishikawa, S., Nemoto, R., Rinsho, K., Yazaki, T., Koiso, K., Takahashi, S., Kitagawa, R.: Long-term intra-arterial infusion chemotherapy with Adriamycin for advanced bladder cancer S 51
Kaplan, A. M., see Armstrong, R. D., et al. 139
Kasukabe, T., see Honma, Y., et al. 73
Kasukabe, T., see Honma, Y., et al. 77
Kataoka, T., see Shimizu, M., et al. 144
Kawabata, T., see Ohi, Y., et al. S 83
Kawahara, M., see Ohi, Y., et al. S 83
Kaye, S., see Welsh, J., et al. 66
Kaye, S. B., see Stuart-Harris, R. C., et al. 69
Keaton, K., see Pavlik, E. J., et al. 8
Kenady, D. E., see Pavlik, E. J., et al. 8
Kerpel-Fronius, S., see Kralovánszky, J., et al. 167
Kim, S. K., An, H. J., Cho, J. H.: Intravesical instillation therapy with Adriamycin for bladder cancer in the Korean study group S 22
Kimball, P. M., Hixon, S., Ellis, N., Arcolano, L.: Selective sensitivity of malignant cells to adriamycin 137
Kitagawa, R., see Kanoh, S., et al. S 51
Klaassen, D. J., see Wu Wei, J., et al. 86
Kobayashi, T., see Mishina, T., et al. S 89
Koch, T. H., see Banks, A. R., et al. 91
Koiso, K., see Kanoh, S., et al. S 51
Koiso, K., see Niijima, T., et al. S 79
Koiso, K., see Ohtani, M., et al. S 64
Kolarić, K., Roth, A.: Phase II clinical trial of *cis*-dichlorodiammine platinum (*cis*-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer 108
Kotake, T., Usami, M., Miki, T., Kuroda, M., Obata, K., Osafune, M., Fujioka, H., Takasugi, Y.: Combination chemotherapy including Adriamycin for advanced transitional cell carcinoma of the urinary tract S 38
Koziner, B., see Straus, D. J., et al. 80
Kralovánszky, J., Prajda, N., Kerpel-Fronius, S., Gál, F., Szentirmay, Z.: Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa 167
Kufe, D., see Fram, R., et al. 43
Kuroda, M., see Kotake, T., et al. S 38

Lauder, I., see Child, J. A., et al. 153
Lazarus, P., Germina, J. St., Dufour, M., Palmer, G., Wallace, D., Panasci, L. C.: Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro 159

Lee, B. J., see Straus, D. J., et al. 80
Lendon, M., see Jackson, H., et al. 200
Lerner, H. J., see Falkson, G., et al. 94
Lister, T. A., see Rohatiner, A. Z. S., et al. 56
Liu, R. H., see Jiang, T. L., et al. 1
Lucas, S. B., see Wilkinson, P. M., et al. 196
Lund, B., see Dombernowsky, P., et al. 51

Machida, T., see Tashiro, K., et al. S 43
Madajewicz, S., see Pendyala, L., et al. 23
Maegawa, M., see Mishina, T., et al. S 89
Major, P., see Fram, R., et al. 43
Malpas, J. S., see Rohatiner, A. Z. S., et al. 56
Mangioni, C., see Sessa, C., et al. 33
Martinez-Pineiro, J. A., see Smith, P. H., et al. S 25
Masuda, F., see Tashiro, K., et al. S 43
Matsumura, Y., Ozaki, Y., Ohmori, H., Okayama Urological Cancer Collaborative Group (OUCCG): Intravesical Adriamycin chemotherapy in bladder cancer S 69
McAuliffe, C. A., see Sharma, H., et al. 5
McCraken, J. D., see Bukowski, R. M., et al. 48
McGown, A. T., Ward, T. H., Fox, B. W.: Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures 113
Miki, T., see Kotake, T., et al. S 38
Milano, G., Thyss, A., Renee, N., Schneider, M., Namer, M., Boublil, J. L., Lalanne, C. M.: Plasma Levels of 7-Hydroxymethotrexate after High-Dose Methotrexate Treatment 29
Milstead, R., see Welsh, J., et al. 66
Minowa, T., see Nakagami, Y., et al. S 47
Mishina, T., Kobayashi, T., Maegawa, M., Nakao, M., Nakagawa, S.: Development and clinical application of an AFC regimen (Adriamycin, Futraful, Cytosine arabinoside) for superficial bladder tumors S 89
Mittelman, A., see Gaver, R. C., et al. 139
Montgomery, J. A., see Sirotnak, F. M., et al. 205
Money, C. A., see Stuart-Harris, R. C., et al. 69
Moriwaki, S., see Uyama, T., et al. S 59
Mulder, J. H., see Smith, P. H., et al. S 25
Muss, H. B., see Shipp, S. K., et al. 130
Muss, H. B., see Jackson, D. V., Jr., et al. 191
Myers, J., see Straus, D. J., et al. 80

Nagata, S., see Ohi, Y., et al. S 83
Nagell, J. R. van, see Pavlik, E. J., et al. 8
Nakagami, Y., Minowa, T., Tozuka, K., Hiraoka, Y., Chin, H.: Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy S 47
Nakagawa, S., see Mishina, T., et al. S 89
Nakamura, M., see Shimizu, M., et al. 144
Nakao, M., see Mishina, T., et al. S 89
Nemoto, R., see Kanoh, S., et al. S 51
Nemoto, S., see Kanoh, S., et al. S 51
Nguyen, B. T., Cohen, M. B., Sadée, W.: Guanine ribonucleotide depletion in mammalian cells. A target of purine antimetabolites 117
Niijima, T., Koiso, K., Akaza, H., Japanese Urological Cancer Research Group for Adriamycin: Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer S 79
Niijima, T., see Ohtani, M., et al. S 64
Nogeirie, C. P., see Bhasin, R. R. 106
Nomura, H., see Honma, Y., et al. 73
Nomura, H., see Honma, Y., et al. 77

Obata, K., see Kotake, T., et al. S 38
Ohi, Y., Okamoto, K., Kawabata, T., Hanafusa, A., Fai, C. Y., Kakinoki, T., Kawahara, M., Asechi, S., Sakamoto, N., Nagata, S., Yagi, S.: Minimization of inflammation in the treatment of bladder tumors by intravesical instillation of Adriamycin S 83
Ohishi, Y., see Tashiro, K., et al. S 43
Ohmori, H., see Matsumura, Y., et al. S 69
Ohtani, M., Fukushima, S., Ito, N., Koiso, K., Niijima, T.: Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats S 64
Okabe-Kado, J., see Honma, Y., et al. 73
Okabe-Kado, J., see Honma, Y., et al. 77
Okamoto, K., see Ohi, Y., et al. S 83
Okayama Urological Cancer Collaborative Group, see Matsumura, Y., et al. S 69
O'Neill, P. A., see Wilkinson, P. M., et al. 196
Oosterlinck, W., see Schulman, C. C., et al. S 32
Oosterom, A. T. Van, see Smith, P. H., et al. S 25
Osafune, M., see Kotake, T., et al. S 38
Osieka, R., Glatte, P., Pannenbäcker, R., Schmidt, C. G.: Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system 147
Owens, S., see Sharma, H., et al. 5
Ozaki, Y., see Matsumura, Y., et al. S 69

Palmer, G., see Lazarus, P., et al. 159
Panasci, L. C., see Lazarus, P., et al. 159
Pannenbäcker, R., see Osieka, R., et al. 147
Pannuti, F., see Camaggi, C. M., et al. 19
Pantarotto, C., see Garattini, E., et al. 51
Parsons, C. A., see Stuart-Harris, R. C., et al. 69
Pauw, M. De, see Smith, P. H., et al. S 25
Pavlik, E. J., Kenady, D. E., Nagell, J. R. van, Keaton K., Hanson, M. B., Donaldson, E. S., Griffen, W. O., Flanigan, R. C.: Properties of Anticancer Agents Relevant to in vitro Determinations of Human Tumor Cell Sensitivity 8
Pavone-Macaluso, M., Tripi, M., Ingargiola, G. B.: Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors S 16
Pecoreili, G., see Sessa, C., et al. 33
Pendyala, L., Greco, W., Cowens, J. W., Madajewicz, S., Creaven, P. J.: Pharmacokinetics of *cis*-Dichloro-Trans-Dihydroxy-bis-Isopropylamine Platinum IV (CHIP) in Patients with Advanced Cancer 23
Peters, J. H., see Abra, R. M., et al. 98
Pittman, A., see Gaver, R. C., et al. 139
Porpaczy, P., Schmidbauer, C. P., Georgopoulos, A., Endler, A. T.: Pharmacokinetics of high-dose methotrexate in dogs. An experimental model with diffusion chambers 172
Prajda, N., see Kralovánszky, J., et al. 167
Pretorius, H. L., see Falkson, G., et al. 203

Ramseur, W., see Shipp, S. K., et al. 130
Renee, N., see Milano, G., et al. 29
Richards, B., see Smith, P. H., et al. S 25
Richards, F. C., see Shipp, S. K., et al. 130
Richards, F., II, see Jackson, D. V., Jr., et al. 191
Rinsho, K., see Kanoh, S., et al. S 51
Robinson, B. A., see Colls, B. M., et al. 188
Robson, R. A., see Colls, B. M., et al. 188

Rohatiner, A. Z. S., Balkwill, F. R., Malpas, J. S., Lister, T. A.: Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML) 56
Rosenthal, D., see Fram, R., et al. 43
Roth, A., see Kolarić, K. 108

Sadée, W., see Nguyen, B. T., et al. 117
Sakamoto, N., see Ohi, Y., et al. S 83
Salmon, S. E., see Jiang, T. L., et al. 1
Sangster, C., see Welsh, J., et al. 66
Santarossa, M., see Veronesi, A., et al. 35
Schmidbauer, C. P., see Porpaczy, P., et al. 172
Schmidt, C. G., see Osieka, R., et al. 147
Schmid, F. A., see Sirotnak, F. M., et al. 205
Schoeman, H. S., see Falkson, G., et al. 203
Schulman, C. C., Denis, L. J., Oosterlinck, W., Sy, W. De, Chantrie, M., Bouffioux, C., Cangh, P. J. Van, Erps, P. Van: Early adjuvant Adriamycin in superficial bladder carcinoma S 32
Seifert, W. E., Jr., Stewart, D. J., Benjamin, R. S., Caprioli, R. M.: Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered *cis*-dichlorodiammineplatinum (II) 120
Sessa, C., D'Incalci, M., Colombo, N., Pecorelli, G., Mangioni, C.: Lack of activity of cyclophosphamide in ovarian cancer patients refractory to *cis*-dichlorodiammine platinum 33
Sharma, H., Thatcher, N., Baer, J., Zaki, A., Smith, A., McAucliffe, C. A., Crowther, D., Owens, S., Fox, B. W.: Blood clearance of radioactively labelled *cis*-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients 5
Shiba, D. A., Weinkam, R. J.: The in vivo cytotoxic activity of procarbazine and procarbazine metabolites against L1210 ascites leukemia cells in CDF_1 mice and the effects of pretreatment with procarbazine, phenobarbital, diphenylhydantoin, and methylprednisolone upon in vivo procarbazine activity 124
Shimizu, M., Nakamura, M., Kataoka, T., Iwaguchi, T.: Mechanism of the antitumor activity of 5,5′-bis(2′-tetrahydropyranyl) secalonic acid D against Meth-A 144
Shipp, S. K., Muss, H. B., Westrick, M. A., Cooper, M. R., Jackson, D. V., Richards, F. C., White, D. R., Stuart, J. J., Christian, R. M., Ramseur, W., Spurr, C. L., Case, D.: Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA) 130
Simmons, A. V., see Child, J. A., et al. 153
Sirotnak, F. M., Schmid, F. A., Temple, C., Jr., Montgomery, J. A.: Optimum scheduling during combination chemotherapy of murine leukemia. Additional examples of schedule-dependent synergism between S-phase-specific antimetabolites and agents inducing mitotic or pre-mitotic (G_2) arrest 205
Smith, A., see Sharma, H., et al. 5
Smith, P. H., Child, J. A., Mulder, J. H., Oosterom, A. T. Van, Martinez-Pineiro, J. A., Richards, B., Stoter, G., Dalesio, O., Pauw, M. De, Sylvester, R.: Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG) S 25
Smyth, R. D., see Gaver, R. C., et al. 139
Spaulding, J. T.: Intravesical chemotherapy in the United States. An overview S 5
Spurr, C. L., see Shipp, S. K., et al. 130
Spurr, C. L., see Jackson, D. V., Jr., et al. 191
Stewart, D. J., see Seifert, W. E., Jr., et al. 120
Stone, J., see Child, J. A., et al. 153
Stoter, G., see Smith, P. H., et al. S 25
Straus, D. J., Myers, J., Koziner, B., Lee, B. J., Clarkson, B. D.: Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV) 80
Strocchi, E., see Camaggi, C. M., et al. 19
Stuart, F., see Welsh, J., et al. 66
Stuart, J. J., see Shipp, S. K., et al. 130
Stuart-Harris, R. C., Harper, P. G., Parsons, C. A., Kaye, S. B., Mooney, C. A., Gowing, N. F., Wiltshaw, E.: High-dose alkylating therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma 69
Sy, W. De, see Schulman, C. C., et al. S 32
Sylvester, R., see Smith, P. H., et al. S 25
Szentirmay, Z., see Kralovánszky, J., et al. 167

Takahashi, S., see Kanoh, S., et al. S 51
Takasugi, Y., see Kotake, T., et al. S 38
Tashiro, K., Machida, T., Masuda, F., Ohishi, Y.: Combination chemotherapy for advanced bladder cancer with Adriamycin, cyclophosphamide, and 5-fluorouracil S 43
Temple, C., Jr., see Sirotnak, F. M., et al. 205
Thatcher, N., see Sharma, H., et al. 5
Thatcher, N., see Wilkinson, P. M., et al. 196
Thorogood, J., see Child, J. A., et al. 153
Thyss, A., see Milano, G., et al. 29
Tirelli, U., see Veronesi, A., et al. 35
Tisch, G. W., see Colls, B. M., et al. 188
Torti, F. M., Harker, W. G.: Chemotherapy of advanced transitional cell carcinoma of the uroepithelium S 1
Tozuka, K., see Nakagami, Y., et al. S 47
Trahey, T. F., see Jackson, D. V., Jr., et al. 191
Tripi, M., see Pavone-Macaluso, M., et al. S 16
Trovo, M. G., see Veronesi, A., et al. 35
Tsushima, S., see Honma, Y., et al. 73
Tsushima, S., see Honma, Y., et al. 77
Tumolo, S., see Veronesi, A., et al. 35

Umeyama, T., see Kanoh, S., et al. S 51
Usami, M., see Kotake, T., et al. S 38
Uyama, T., Moriwaki, S., Yonezawa, M., Fujita, J.: Intra-arterial Adriamycin chemotherapy for bladder cancer. Semiselective intra-arterial chemotherapy with compression of the femoral arteries at the time of injection S 59

Vandendris, M., Dumont, P., Heimann, R., Atassi, G.: Development and characterization of a new murine renal tumor model. Chemotherapeutic results 182
Veronesi, A., Zagonel, V., Santarossa, M., Tirelli, U., Galligioni, E., Trovo, M. G., Tumolo, S., Grigoletto, E.: *cis*-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma 35
Vorobiof, D. A., see Falkson, G., et al. 94

Wallace, D., see Lazarus, P., et al. 159
Ward, T. H., see McGown, A. T., et al. 113
Warrell, R. P., Jr., Coonley, C. J., Burchenal, J. H.: Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (α-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)] 134

Weinkam, R. J., see Shiba, D. A. 124
Wells, H. B., see Jackson, D. V., Jr., et al. 191
Welsh, J., Stuart, F., Sangster, C., Milstead, R., Kaye, S., Cash, H., Charlton, D., Calman, K.: Oral levonantradol in the control of cancer chemotherapy-induced emesis 66
Westrick, M. A., see Shipp, S. K., et al. 130
Whitacre, M., see Gerad, H., et al. 162
White, D. R., see Shipp, S. K., et al. 130
White, D. R., see Jackson, D. V., Jr., et al. 191
Wilkinson, P. M., O'Neill, P. A., Thatcher, N., Lucas, S. B.: Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma 196
Wiltshaw, E., see Stuart-Harris, R. C., et al. 69
Wu-Wei, J., Hickie, R. A., Klaassen, D. J.: Inhibition of human breast cancer colony formation by anticalmodulin agents: Trifluoperazine, W-7, and W-13 86

Yagi, S., see Ohi, Y., et al. S 83
Yagoda, A.: Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center S 9
Yazaki, T., see Kanoh, S., et al. S 51
Yonezawa, M., see Uyama, T., et al. S 59

Zagonel, V., see Veronesi, A., et al. 35
Zaki, A., see Sharma, H., et al. 5
Zebini, E., see Camaggi, C. M., et al. 19
Zupi, G., see Greco, C., et al. 38